E-mail  |   Log in
News Center
Ningbo Aucheer Biotechnology Co., Ltd
audir
audir
Industry News|Commercialization of Microfluidics

Industry News|Commercialization of Microfluidics

  • Categories:Industry form
  • Author:
  • Origin:
  • Time of issue:2019-11-06
  • Views:0

(Summary description)Microfluidic technology is an emerging technology platform that can realize the automation, miniaturization and multiplexing of laboratory equipment, drug screening technology and in vitro diagnostic equipment. Microfluidic technology has the potential to reduce the operating time and cost of analytical equipment. , Especially in the medical field, in the past two decades, there have been many companies commercializing microfluidic technology.

Industry News|Commercialization of Microfluidics

(Summary description)Microfluidic technology is an emerging technology platform that can realize the automation, miniaturization and multiplexing of laboratory equipment, drug screening technology and in vitro diagnostic equipment. Microfluidic technology has the potential to reduce the operating time and cost of analytical equipment. , Especially in the medical field, in the past two decades, there have been many companies commercializing microfluidic technology.

  • Categories:Industry form
  • Author:
  • Origin:
  • Time of issue:2019-11-06
  • Views:0

 

 

Click "Ao Cheng Biology" above to follow and get the latest information!

 

Microfluidics technology is an emerging technology platform that can realize automation, miniaturization and multiplexing of laboratory equipment, drug screening technology and in vitro diagnostic equipment,Microfluidic technology has the potential to reduce the operating time and cost of analytical equipment, especially in the medical field.In the past two decades, many companies have commercialized microfluidic technology.

 

  Microfluidic Product Market 

 

In 2013, the market value of microfluidics was approximately USD 1.6 billion. With the expected compound annual growth rate (CAGR) of 18-29%, it has reached US$3.6-5.7 billion in 2018. Such a high growth rate is largely due to the latest advances in biotechnology, includingGene sequencing and POCT immediate diagnosis.

 

 

Gene Sequencing

 

 

With the completion of the Human Genome Project in 2003 and the emergence of next-generation sequencing,Microfluidic technology has been used to increase the degree of automation and reduce the turnaround time of genomics.

 

To further simplify the sample preparation required for next-generation sequencing, RainDance Technologies Inc. has developed a single-molecule skin drop system for digital PCR. Each drop contains a uniform amount of genomic DNA and primers. therefore,The system enhances reproducibility and can target specific regions of the genome. It can also be used for applications such as drug development and biomarker identification.

 

POCT even if diagnosed

 

 

The second area that benefits from microfluidic technology is POCT point-of-care diagnosis. For example, Abbott Laboratories' i-STAT system integrates microfluidic technology and electrochemical detection to analyze the chemical components in the blood.

Solving major clinical problems (especially in developing countries) requires practical and appropriate POC equipment, not technologically novel equipment.Daktari Diagnostics Inc. uses microfluidic technology to integrate sample preparation and analysis into one device. The device contains a microfluidic differential counter that can quantify CD4 + or CD8 + immune cells in blood samples. The device has the same accuracy as traditional flow cytometry and has the potential to reduce the cost of HIV diagnosis.

 

  Challenges Facing The Commercialization Of Microfluidic Devices 

 

In the field of microfluidics, the academic publications of proof-of-concept devices are very abundant. However, due to the lack of market verification, microfluidic devices currently face the following challenges.

 

 

Standardization

 

 

Scholars in microfluidics research are usually unable to quote repeatability statistics, nor can they quantify chip-to-chip (batch-to-batch) differences in a given prototype or manufacturing method. Due to the lack of standardization in the entire field, new types of microfluidic analysis (including protocols, equipment and materials) for specific applications are often incompatible with existing technologies on the market.

 

Integrated

 

 

Another benefit of standardization is divide and conquer. Many academic groups and many start-up companies have developed fluid delivery and control, signal detection and microfabrication methods with potentially transformative capabilities. However, the successful operation of technically complex assays requires a seamless and automated way to perform all assay procedures. And standardized component manufacturing can greatly reduce the difficulty of product development and promotion, and will also play a greater role in cost control.

 

Understand the "market" and clinical issues

 

 

As a medical technology, POC diagnosis requires a lot of development funds. Therefore, raising funds is the first task for researchers to bring promising technologies to the market. The value of POC equipment varies by application. During the "prime time" of patients with a heart attack, POC diagnostic cardiac markers can immediately give the correct treatment plan. For pregnancy testing, POC equipment should pay more attention to the convenience of use. The benefits of POC testing outweigh its disadvantages, because changing the existing routine diagnostic program itself is also a high-input activity.

 

Market size

 

 

POC tests accounted for 31% of the diagnostic market (glucose tests accounted for 18%, professional POC products accounted for 11%, and over-the-counter drugs accounted for 2%). At present, the detection of infectious diseases and cardiac markers has been transferred from centralized laboratories to POC. Another example is the field of nucleic acid testing, which only accounts for 8% of the current diagnostic market, but is still growing by 7% every year, and is another major market for microfluidic POC equipment.

 

  Future outlook

 

In order to promote this technology on a large scale, microfluidic products must far exceed existing technologies in performance and functionality, or provide clinical diagnostic results at a lower cost.At present, microfluidic devices should not wait for killer applications, but aim at the segmented areas of market segments, and realize that existing technologies cannot meet the needs of specific customers.Combining standardized development and integrated production, solving practical clinical problems, using materials and technical routes that can be mass-produced, so that microfluidic technology can play its commercial potential.

 

Aucheer Microfluidic Fluorescence Immunoquantitative Detection Technology Platform

 

Ningbo Aocheng Biotechnology Co., Ltd. is a high-tech biological enterprise focusing on the early detection, diagnosis, prevention and monitoring of diseases. By providing reliable, fast and convenient in vitro diagnostic products, it can provide accurate test results for diagnosis and treatment. At present, the company's biomedical team continues to conduct in-depth exploration and prospective research in the field of high-risk diseases for pregnant women such as hypertension,combined with the self-developed microfluidic technology platform, we will be committed to providing leading maternal and child health clinical diagnosis solutions.

相关资讯

Aucheer
Contact:86-574-87732259
Technical Support:400-008-6588
Aucheer
Business Mailbox:info1@aucheer.net
HR Mailbox :hr@aucheer.net
Aucheer
Address: No. 885, Chunhua Road, Haishu District, Ningbo City, Zhejiang Province
North 4th Floor, Science and Technology Building, Ningbo Haichuang Park
Aucheer
Auchen Bio
Aucheer
Auchen Medical

© 2021 Ningbo Aucheer Biotechnology Co., Ltd | 浙ICP备17032133号-2Powered by www.300.cn